Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020 / Hydroxicloroquine and remdesivir publications: update September 2020

El debate científico sobre las terapéuticas eficaces y seguras para tratar la Covid-19 desde su comienzo en enero 2020 ha dado lugar a miles de publicaciones con sus implicaciones sociales y económicas respecto a fabricantes farmacéuticos, investigadores clínicos y publicaciones científicas. En este nuevo comentario se resumen las publicaciones de junio a septiembre de 2020 sobre los dos medicamentos más contrapuestos en muchos ámbitos clínicos: hidroxicloroquina y remdesivir

The scientific debate about the effective and safe therapies to treat the COVID-19 from its beginning in January 2020 has led to thousands of publications with their social and economic implications related to pharmaceutical manufacturers, clinical researchers and scientific publications. In this new comment, there are summarized the publications from June to September, 2020 about the two more opposing medications in many clinical settings: hydroxychloroquine and remdesivir

Estado de situación en Europa del Pharmaceutical Care / State of Pharmaceutical Care in Europe

En 2019 la revista Research in Social and Administrative Pharmacy, editada por ELSEVIER en California, con un factor de impacto de 2,873 para los últimos 5 años, ha publicado los resultados de un estudio sobre implementación de servicios de Atención Farmacéutica en las farmacias comunitarias de Europa en los años 2016-2017. Se realizan dos estudios independientes, ambos mediante envío de cuestionarios a profesionales seleccionados y relacionados con la farmacia comunitaria. El primero intenta conocer qué tipo de servicios cognitivos se ofrecen en cada país y su remuneración. Se publica en Febrero con resultados muy variados. El segundo, publicado en Noviembre, profundiza en la implementación de solo uno de aquéllos servicios: la Revisión de Medicación. Aprovecha la definición y clasificación que PCNE hace en 2016 de ese servicio y con ello consigue establecer un mapa de la implantación real en 34 países de Europa así como sus características profesionales y de remuneración. Parece de interés para España conocer estos datos ahora que algunas leyes autonómicas programan la implementación y coordinación de servicios de AF de acuerdo con las corporaciones farmacéuticas

The scientific magazine Research in Social and Administrative Pharmacy, edited by ELSEVIER in California, with an impact factor of 2,873 for the last 5 years published in 2019 the outcomes of a study about the implementation of Pharmaceutical Care Services in the community pharmacies of Europe over the years 2016 - 2017. Two independent studies were carried out, both through questionnaires sent to selected professionals linked to the community pharmacy. The first one tried to find out which kind of cognitive services are offered in each country and their remuneration. It was published in February with very varied outcomes. The second one, published in November, deepened in the implementation of only one of those services: the Medication Review. It took advantage of the definition and classification done by PCNE of that service and so it achieved to establish a map of the actual implementation in 34 European countries together with its professional characteristics and its remuneration. It seems interesting for Spain to know these data now that some autonomous laws plan the implementation and coordination of pharmaceutical care services in accordance with the pharmaceutical corporations

La revisión de medicación a examen / No disponible

No disponible

Estudio preliminar de los tratamientos de infecciones del tracto urinario registrados en oficinas de farmacia como base para un estudio del impacto de la atención farmacéutica en estos pacientes / Preliminary study of the treatments of urinary tract infections recorded in community pharmacies as the basis for a study of the impact of pharmaceutical care in these patients

Objetivos: Conocer el perfil de los pacientes que acuden a las farmacias para iniciar un tratamiento de la infección del tracto urinario, el tipo de medicamentos prescrito y la presencia de recurrencia en cada paciente. Método: Estudio prospectivo de recogida de datos de las dispensaciones efectuadas en 7 farmacias de Asturias durante 4 meses y siguiendo el procedimiento descrito en FORO 2008. El dato de recurrencia se obtuvo mediante preguntas adicionales a la entrevista-tipo usada en el estudio. Resultados: Se estudiaron 110 casos, de 20 hombres (18,2%) y 90 mujeres (81,8%). La media de edad en los hombres fue de 62,6 años (rango: 23-85) y en las mujeres de 58,7 (rango: 18-94). El 59% de las mujeres tenía más de 50 años y había 4 embarazadas (4,5%). En las mujeres, el 43% de las prescripciónes fueron quinolonas (33% norfloxacino y 10% ciprofloxacino), el 41% fosfocina y el 12% betalactámicos. En los hombres, el 75% de las prescripciones fueron quinolonas (50% ciprofloxacino y 25% norfloxacino), el 15% fosfocina y el 5% amoxicilina-clavulánico. Las pautas fueron homogéneas para cada tipo. De los 110 pacientes entrevistados, el 50% recordaba haber tenido una infección urinaria en los últimos 6 meses o más de una en el último año. No se obtuvo este dato en el 13% de los casos. Conclusiones: El perfil demográfico de los pacientes coincide con el de otros estudios publicados. El patrón de prescripción es muy homogéneo en cuanto a la selección de los principios activos, acorde con la bibliografía publicada desde 2003. Las pautas de prescripción parecen estar más influidas por las presentaciones disponibles en el mercado que por las guías clínicas. La presencia de recurrencias parece elevada, aunque no hay datos cuantitativos disponibles de este problema en nuestro entorno (AU)

Objectives: To collect the demographic data of patients who come to pharmacies to initiate drug treatment for a urinary tract infection (UTI), to and determine the classes of drugs prescribed and the incidence of recurrence in each patient. Method: A prospective study involving the collection of data on the drugs prescribed for UTI dispensed at seven pharmacies in Asturias over a four-month period, following the procedure for drug dispensing described in the FORO 2008 document. The data on recurrence was obtained by including additional questions in the interview employed in the study. Results: We studied 110 cases: 20 men (18.2%) with a mean age of 62.6 years (range: 23-85 years) and 90 women (81.8%) with a mean age of 58.7 (range: 18-94 years); 59% of the women were over 50 years of age. Four of the women were pregnant (4.5%). The kinds of drugs prescribed to women (n=90) were: quinolones (43% [norfloxacin in 33% and ciprofloxacin in 10%]); fosfomycin in 41% and beta-lactams in 12%. For men (n=20) they were: quinolones (75% [ciprofloxacin in 50% and norfloxacin in 25%]); fosfomycin in 15% and betalactams in 5%. Dosing was very similar for each class. Of the 110 patients interviewed, 50% recalled having had another UTI within the preceding six months or at least two over the previous year. Data concerning recurrence was not obtained in 13% of the cases. Conclusions: The demographic profile of the patients is similar to that described in other primary care studies on UTI in the literature. The types of drugs prescribed do not vary widely, following recent indications of clinical guidelines for Primary Care since 2003; not so the dosing, which seems to be more influenced by the presentations available in the pharmaceutical market than by the clinical guidelines. The rate of recurrence seems high, but we have no quantitative reference data on this problem in our region (AU)

Definiciones y conceptos de FORO de Atención Farmacéutica / No disponible

No disponible

[Pharmaceutical care in people who have had acute coronary episodes (TOMCOR study)]. / Atención farmacéutica en personas que han sufrido episodios coronarios agudos (Estudio TOMCOR).

BACKGROUND: This study evaluates the effects on coronary patients of a new practice in community pharmacies called Pharmaceutical Care (PhC) as compared to the traditional pattern of pharmacy practice. It attempts to ascertain whether pharmaceutical care is feasible in addition to ascertaining differences in effectiveness for coronary patients' pharmacotherapeutic health outcomes, potentially attributable to PhC. METHODS: A randomized prospective controlled-intervention study was conducted in 83 community pharmacies in the provinces of Asturias, Barcelona, Madrid and Biscay in a one-year monitoring of the drug-use of 735 patients at the start of the study (330 intervention patients and 405 control) and 600 at the end. RESULTS: Differences were fund in favor of the intervention group in: a) the use of health care services as a morbidity indicator such as frequency of hospital emergency room visits 1.27 I (CI95%; 1.10-1.44) and 1.63 C (CI95%; 1.36-1.90) or average length-of-stay in Intensive Care Units 2.46 I (CI95%; 1.56-3.36) and 5.87 C (CI95%; 3.57-8.17), both due to coronary causes; b) health-related quality of life score (physical functioning dimension difference of 4.7 (p < 0.05); c) average patient knowledge of coronary heart disease risk factors having improved by 10% (p < 0002-0.007 depending on dimension); d) patient knowledge of the name and identification of their drugs having improved by 10% (p < 0.001) along with their subjective perception of the antiagregans drugs relative importance having improved by 12% (p < 0.009) and effects of beta-blockers having improved by 25% (p < 0.02); e) average satisfaction with pharmaceutical care service and perception of pharmacist's professional competence having improved by 2% (p < 0.000 to 0.05 depending on dimension). CONCLUSIONS: A decrease in emergency health care demand due to coronary causes, a fewer number of patient hospitalizations and a shorter length-of-stay in Coronary Intensive Care Units due to hospitalization regarding coronary patients on pharmaceutical care would suggest that patients who suffered an acute coronary heart episode made a better use of drugs and would tend to be less ill. Furthermore, coronary patients who received pharmaceutical care services showed a better knowledge of the reasons for their pharmacotherapy and therefore took better advantage of health care resources and improved their health condition.

[The new pharmacy practice: can pharmaceutical intervention improve therapeutical efficiency]. / La nueva atención farmacéutica: puede la intervención farmacéutica mejorar la eficiencia terapéutica?

BACKGROUND: The pharmaceutical activity has experienced over the last 50 years an important evolution in terms of concepts and contents affecting not only pharmacists but the whole health professionals. The subject of this study were the characteristics and implications of that change. METHODS: We review the main conditions leading to this change and characteristics of the new pharmaceutical activity focused mainly on the filtrate and alert about drug related problems and the professional intervention facing a proper resolution. RESULTS AND CONCLUSIONS: Some preliminary results from an investigation about the mentioned conditions are presented supporting the idea that this new proposed pharmaceutical intervention model can actually improve benefits on therapeutical effectiveness and save resources.

[Detection of prescription errors in drug dispensing: incidence and typology]. / Detección del error de prescripción en la dispensación farmacéutica: incidencia y tipología.

OBJECTIVE: Description and quantification of the types of prescribing errors during dispensing activities at community pharmacies. DESIGN: Descriptive transversal study carry out along four weekly periods. SITE. Eighteen pharmacies from six of the spanish autonomous regions dispensing prescription orders mainly issued by the National Health Service. PATIENTS AND OTHER TAKING PART: 37,321 prescriptions of specialties dispensed by the mentioned pharmacies along the four week period. MAIN MEASUREMENTS AND RESULTS: An unstructured questionnary was applied to all persons asking for one of the mentioned prescriptions. When an error was suspected, a second structured questionnary was applied by the pharmacist to the order bearer and the answers plus the information contents at the prescription form was collected on a data-sheet. Data were processed on a dBase and SPSS programs. Incidence detected error of 1.35%. Types of error classified into five categories. Study of the variability of error detection by week and by pharmacy. Analysis and comparison with references of the "order author" data and "prescriptor" data. CONCLUSIONS: Our global incidence of detected error was lower in relation with other studies. We found short differences by weeks and large by pharmacies. Inadequate definition of the drug was the most frequent type of error. The detection frequency of posology error was higher following the use of the new prescription order model. The number of orders from different prescriptor/author was larger in our study in relation to the notified by other studies.